Crystagen (Glu-Asp-Pro)
EDP tripeptide, Glu-Asp-Pro, H-Glu-Asp-Pro-OH, Kristagen
Crystagen is a synthetic tripeptide, Glu-Asp-Pro, from the Khavinson school of short peptide bioregulators, identified as one of the active fragments within the thymus extract thymalin. It is sold as an immune 'bioregulator' but has no registered human trials anywhere, and the entire indexed evidence base naming it is a single Russian-language tissue study. Its sequence is also widely misreported by vendors.
Mechanism
Crystagen is a synthetic tripeptide, Glu-Asp-Pro (EDP), one of the short 'peptide bioregulators' developed at the St Petersburg Institute of Bioregulation and Gerontology. Khavinson's group identifies it as one of the active short-peptide constituents of the calf thymus extract thymalin, alongside Glu-Trp (thymogen) and Lys-Glu (vilon), and assigns it a thymic and lymphoid tissue target with reported activation of B-cell populations.
The proposed mechanism is the general Khavinson model applied to this peptide: that peptides of two to seven residues penetrate the cell and the nucleus, interact with nucleosomes, histones and both single- and double-stranded DNA, and recognise specific sequences in gene promoters, thereby modulating tissue-specific gene expression. The group has also published on uptake of ultrashort peptides via POT (proton-coupled oligopeptide transporter) and LAT (large neutral amino acid transporter) carriers as the route into cells.
This model deserves direct scrutiny rather than restatement. Sequence-specific recognition of promoter DNA by an unmodified tripeptide, with the binding affinity and selectivity required to regulate transcription in a cell, is not a mechanism supported by mainstream nucleic-acid biochemistry. DNA-binding specificity in known systems requires substantially larger, structured protein domains making multiple co-ordinated contacts across the major groove. The model has been advanced almost exclusively by one research school over three decades and has not been reproduced as a general mechanism of peptide action by independent structural biology groups. Readers should treat it as an unvalidated claim, not as an explanation.
One further point on identity. Vendor listings for crystagen disagree with each other, variously giving Glu-Asp-Pro, Glu-Asp-Gly and Thr-Lys-Asp. The sequence given here, Glu-Asp-Pro, is the one stated by Khavinson in the peer-reviewed literature. Anyone buying material labelled crystagen should understand that they may not be receiving the compound described in the research.
What the research shows
There is essentially no human evidence for crystagen, and this should be stated without hedging. A PubMed search returns a single indexed study naming the peptide: Chervyakova and colleagues (Advances in Gerontology, 2014), a Russian-language study of immunoprotective peptide activity in spleen during ageing, examining vilon, thymogen, crystagen and a peptide designated R-1. The paper states that crystagen activates B-cells of the immune system but does not cause cell renewal in the ageing spleen. That is, the effect it reports is partial even within its own laboratory framing. This is tissue-level work, not clinical evidence. No trial of crystagen is registered on ClinicalTrials.gov.
A figure that circulates widely deserves specific attention. Khavinson's 2021 review states that crystagen, in combination with standard treatment, contributed to normalisation of the immunogram in 82% of patients versus 56% in controls. The primary report underlying that figure is not retrievable in the indexed international literature. No sample size, design, randomisation status, blinding, outcome definition or registration is given, and the peptide was given alongside standard treatment rather than alone. A percentage without a retrievable study behind it is not trial evidence and should not be presented as such, and 'normalisation of the immunogram' is in any case a laboratory surrogate, not a clinical outcome that tells a person whether they will get fewer infections or live longer.
Crystagen is sold to consumers as an oral capsule 'bioregulator' and as a lyophilised powder labelled for research use only. That phrase is worth unpacking honestly, because it does a lot of work in this market. 'For research use only' is not a scientific classification and confers nothing about quality, purity or evidence. It is a legal formula that allows an unapproved compound to be sold to the public while the seller avoids making therapeutic claims and avoids the evidentiary standards a medicine must meet. For crystagen the underlying position is simple: no regulator anywhere has assessed it, no controlled human trial has tested it, and the entire published record consists of one tissue study and a set of claims from the institute that invented it.
Evidence assessment
Preclinical only
There are no registered human trials of crystagen anywhere and no randomised controlled trial in the indexed literature; the only PubMed-indexed study naming the peptide is a Russian-language spleen tissue study from the developing institute, and the sole human efficacy figure in circulation appears only in a review by the developers with no retrievable primary report, so the surviving citations are entirely preclinical.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
[Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process] Preclinical only
Verbatim from the abstract: crystagen 'also activates B-cells of the immune system; however, the peptide doesn't cause cell renewal in spleen as it ages'. Vilon and R-1 activated T-helpers; thymogen activated B-cells via reduced apoptosis and increased proliferation.
The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity Limited evidence
States that crystagen, in combination with standard treatment, contributed to normalisation of the immunogram in 82% of patients versus 56% of controls, with particular effect on T-cell immunity markers.
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers Preclinical only
Proposes that di- and tripeptides are transported into cells of various tissues by POT and LAT carriers, providing the transport component of the Khavinson bioregulator model.
Safety
There is no safety data for crystagen worth the name. No toxicology study, no pharmacokinetic study, no systematic adverse event collection, and no controlled human exposure of any kind has been published. Statements that it is 'well tolerated' rest on the absence of reports rather than on any monitoring, and absence of evidence of harm in a literature this thin is not evidence of safety.
On first principles a tripeptide of three proteinogenic amino acids is unlikely to be intrinsically toxic, and oral capsules are likely to be largely hydrolysed in the gut. That is an argument that crystagen probably does very little rather than an argument that it is safe to inject. Lyophilised powder sold for reconstitution and injection carries the risks that actually harm people in this market: unverified identity (particularly acute here given that vendors disagree on the sequence) plus unverified purity, sterility and endotoxin content. Nothing is known about use in autoimmune disease, in pregnancy, in transplant recipients, or alongside immunosuppressive therapy, because nothing has been studied.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation and no authorised status as a food supplement ingredient. Not a licensed medicine in the UK. |
| United States | Not approved by the FDA, never submitted for approval, and not a recognised dietary ingredient. It is sold only under 'research use only' labelling, which permits distribution of an unapproved compound rather than indicating any regulatory review. |
| WADA (sport) | Not named on the WADA Prohibited List, but athletes should assume it is captured by section S0 (unapproved substances), which prohibits any pharmacological substance not addressed by other sections and not currently approved by any governmental regulatory health authority for human therapeutic use. Crystagen is approved by no regulator anywhere, which places it squarely within that description. |
Questions
Glu-Asp-Pro (EDP), a tripeptide. This is the sequence stated by Khavinson in the peer-reviewed literature. Vendor listings frequently disagree, variously giving Glu-Asp-Gly or Thr-Lys-Asp, and some describe it as a tetrapeptide. That disagreement is itself worth noting: if suppliers cannot agree on what molecule they are selling, buyers have no basis for assuming the material matches the research.
None are registered on ClinicalTrials.gov and none appear in the indexed international literature. The only PubMed-indexed study naming crystagen is a 2014 Russian-language laboratory study of spleen tissue during ageing, which found it activated B-cells but did not produce cell renewal. A 2021 review by the compound's developers cites an 82% immunogram normalisation rate in patients given crystagen alongside standard treatment, but the primary report behind that figure is not retrievable and no design details are given, so it cannot be verified or appraised.
The proposed mechanism is the general Khavinson bioregulator model: that very short peptides enter the cell nucleus, bind specific sequences in gene promoters and modulate tissue-specific gene expression, in crystagen's case, in the thymus and lymphoid tissue. This model has been advanced by essentially one research school for three decades without independent structural confirmation, and sequence-specific promoter binding by an unmodified tripeptide is not a mechanism supported by mainstream nucleic-acid biochemistry. Treat it as an unvalidated hypothesis.
It is a legal formula, not a scientific category or a quality standard. It permits an unapproved compound to be sold to consumers while the seller avoids making therapeutic claims and avoids the evidence requirements that apply to medicines. It says nothing about purity, sterility, identity or whether the compound works. For crystagen the substantive position is that no regulator anywhere has assessed it and no controlled human trial has tested it.